海外av无码网址入口_日韩亚洲中字在线_销魂老女人老熟妇69xx_被闺蜜玩sm(女绑女)_无码国产片观看_亚洲伦理在线电影_少妇免费一级黄片_影音先锋国产区免费观看_中文字幕精品人妻一区二区_黄品汇视频app污下载

 

 

 

According to the data, Ningdan New Drug is an innovative company focused on the research and industrialization of new drugs in the field of central nervous system diseases (CNS). The company has established a comprehensive and complete internal research and development platform, including drug chemical synthesis, compound screening, CMC development, DMPK research, in vivo pharmacology research, toxicology research, and clinical research. Currently based on the existing sublingual formulation research and development platform ND-S ®、 Multi target drug development platform ND-M ® ND-C, a compound drug research and development platform ®， We have developed multiple new central nervous system drug projects, which are currently in the clinical research or clinical application stages.

 

 

 

It is reported that Puli Pharmaceutical, as the CMO service provider for this innovative drug project, will leverage its mature international high-end manufacturing and production platform advantages to provide production services for the innovative drug and help accelerate the research and development transformation process of the pipeline. Puli Pharmaceutical is deeply involved in the research, development, and translational production of pharmaceutical formulations, including innovative drug products. This cooperation with Ningdan New Drug fully demonstrates the high recognition of industry partners for Puli Pharmaceutical's clinical translational capabilities in innovative drugs, marking a new stage for Puli Pharmaceutical in the field of innovative drug production.

 

 

 

According to the review, on October 29th, Heyuan Biotechnology and Nuoqing Biotechnology signed a strategic cooperation agreement. The two parties have reached cooperation in the construction of a digitalized biological sample library, clinical biological sample transformation, and full lifecycle services for research and development projects. They are committed to providing compliant, authentic, complete, and traceable one-stop solutions for the development of cell and gene therapy drugs, and jointly promoting more research and development projects to enter clinical practice.

 

 

 

According to the data, Heyuan Biotech focuses on providing one-stop CDMO services for drug developers in the fields of cell and gene therapy, covering preclinical research, CMC pharmaceutical research, clinical sample production, and commercial large-scale production. At present, the company has 15 carrier production lines and 20 cell production lines, which can meet the GMP production requirements for cells and gene therapy products of different scales and characteristics. Both parties will work together to ensure compliance in the development of cell and gene therapy drugs, in order to continuously empower the provision of safer and more effective drugs.

 

 

 

On August 4th, China Resources Pharmaceutical and Tasly also signed a strategic cooperation agreement, and the two sides will cooperate in the innovation and development of traditional Chinese medicine, the development of intelligent herbal models, and the development of drop pill technology and equipment.

 

 

 

In April, Prolo Pharmaceutical signed a Strategic Cooperation Framework Agreement with Zhejiang Heze Pharmaceutical. Prolo Pharmaceutical and Heze Pharmaceutical will carry out comprehensive cooperation in the pharmaceutical field, including project selection, commissioned research and development, production and processing, and market sales. The agreement requires both parties to jointly establish a project initiation team, utilizing their respective resources and channel advantages to select varieties with good market prospects, high clinical value, differentiation, and technical barriers.

 

 

 

In March, China National Pharmaceutical Group and Federal Pharmaceutical reached a strategic cooperation agreement, further strengthening their strategic cooperation in multiple fields and tracks such as industrial chain, supply chain, and innovation chain. Through this strategic signing, China National Pharmaceutical Group Corporation (Sinopharm) will work together with Federal Pharmaceutical to seek multi-faceted cooperation in multiple fields and tracks, and jointly create a future pharmaceutical and health platform.